Insight, China's Pharmaceutical Industry

Shanghai Yizhong Pharma’s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China – Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery

Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a U.S.-based developer of antibodies for rare autoimmune conditions, has...

Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026

Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced a strategic partnership with...

Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026

Shanghai Pharmaceutical Holding Co., Ltd. (HKG: 2607, SHA: 601607) announced a strategic partnership with BeOne...

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced the completion of analysis from...

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026

TransThera Sciences (Nanjing), Inc. (HKG: 2617) and Allist Pharmaceuticals Co., Ltd. (SHA: 688578) have announced...

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced its participation in a...

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Fineline Cube May 27, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received separate clinical...

Company

Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion

Fineline Cube May 27, 2026

Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive...

Company

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

Fineline Cube May 27, 2026

The Global Medical Device Training, Exhibition, Trading and Innovation Center was officially inaugurated this week...

Company Drug

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...

Company Drug

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and its U.S. partner Kailera Therapeutics...

Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026

Insilico Medicine (HKG: 3696) and Human Life Foundation Models (HLFM), a newly established spin-off from...

Company Drug

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in China...

Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026

Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics...

Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026

Shanghai Simpletouch Robot Co., Ltd. has filed its prospectus with the Hong Kong Stock Exchange...

Company Deals

Qingfeng Pharmaceutical Secures Greater China Rights to Merz’s Inbrija Levodopa Inhalation Powder for Parkinson’s Disease OFF Episodes

Fineline Cube May 26, 2026

Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German...

Company Deals

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Fineline Cube May 26, 2026

Peak Pharmaceutical Co., Ltd. announced a strategic partnership with SPH Kyuan Trade, a core subsidiary...

Others

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

Fineline Cube May 26, 2026

Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has...

Insight, China's Pharmaceutical Industry

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Shanghai Yizhong Pharma’s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China – Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635

Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Qingfeng Pharmaceutical Secures Greater China Rights to Merz’s Inbrija Levodopa Inhalation Powder for Parkinson’s Disease OFF Episodes

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

You Missed

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology